Literature DB >> 7096825

Functional assessment of alveolar macrophages: comparison of cells from asthmatics and normal subjects.

P Godard, J Chaintreuil, M Damon, M Coupe, O Flandre, A Crastes de Paulet, F B Michel.   

Abstract

Alveolar macrophages (AM) were obtained by bronchoalveolar lavage (BAL) from seven healthy nonallergic, nonasthmatic donors, 15 patients with allergic bronchial asthma, and six patients with aspirin-sensitive asthma. AM were purified by adherence over 2 hr and cultured for an additional 24 hr. Functional assessment of viable cells was carried out for zymosan phagocytosis and for prostaglandin (PG) E2-PGF2 alpha and thromboxane (Tx) B2 release by resting and zymosan-stimulated AM. The eosinophil count in BAL fluid from allergic asthmatics was higher than that from control subjects (3.9% +/- 1.6% vs 0.4% +/- 0.3%, p less than 0.05) and still greater in BAL from patients with aspirin-sensitive asthma (21.7% +/- 9.0%, p less than 0.01). After the 24 hr of incubation, the AM viability was inversely correlated to the percentage of eosinophils in BAL fluid (r = -0.54, n = 21, p less than 0.02). Zymosan phagocytosis was significantly lower by viable cells from both allergic asthmatics and aspirin-sensitive patients as compared with cells from normal donors (p less than 0.05). Zymosan phagocytosis induced a twofold to threefold increase in the release of PGE2, PGF2 alpha, and TxB2 from AM of normal subjects (p less than 0.01) but only a onefold to twofold increase from AM of allergic asthmatic patients. The stimulated AM from aspirin-sensitive patients released smaller quantities of each product than AM from normal subjects or allergic asthmatic patients (p less than 0.05). We conclude that the viability and functional activity of AM are impaired in asthmatic patients and that these deficits correlate with the percent eosinophilia in the BAL; it is therefore suggested that they may be due to an interaction between eosinophils and AM in the bronchoalveolar lumen.

Entities:  

Mesh:

Year:  1982        PMID: 7096825     DOI: 10.1016/0091-6749(82)90234-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  22 in total

Review 1.  The pharmacology of airway hyperresponsiveness and inflammation.

Authors:  R Pauwels
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Bronchoalveolar lavage in the cat: cytological findings.

Authors:  G M McCarthy; P J Quinn
Journal:  Can J Vet Res       Date:  1989-07       Impact factor: 1.310

Review 3.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

4.  Bronchoalveolar mast cells in extrinsic asthma: a mechanism for the initiation of antigen specific bronchoconstriction.

Authors:  K C Flint; K B Leung; B N Hudspith; J Brostoff; F L Pearce; N M Johnson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-05

Review 5.  Allergic Respiratory Inflammation and Remodeling.

Authors:  Kawa A M Amin
Journal:  Turk Thorac J       Date:  2015-07-01

Review 6.  Role of inflammation in the hyperreactivity of the airways in asthma.

Authors:  K F Chung
Journal:  Thorax       Date:  1986-09       Impact factor: 9.139

Review 7.  PAF antagonists. Their potential therapeutic role in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

Review 8.  Eosinophils in the 1990s: new perspectives on their role in health and disease.

Authors:  A J Wardlaw
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

9.  In vivo uptake of inhaled particles by airway phagocytes is enhanced in patients with mild asthma compared with normal volunteers.

Authors:  J C Lay; N E Alexis; K L Zeman; D B Peden; W D Bennett
Journal:  Thorax       Date:  2008-12-03       Impact factor: 9.139

Review 10.  Analgesics, allergy and asthma.

Authors:  A Szczeklik
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.